XYRA pairs a fast‑acting anti‑arrhythmic with wearable monitoring to transform atrial fibrillation care.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
XYRA pairs a fast‑acting anti‑arrhythmic with wearable monitoring to transform atrial fibrillation care.
Cardiology
Technology Platform
Mixed ion‑channel blocker with esterase metabolism delivering a short half‑life and low tissue accumulation, paired with wearable cardiac monitoring for real‑time AF detection.
Opportunities
Potential to capture a large share of the AF market by offering a safer, fast‑acting drug combined with scalable wearable monitoring, and to generate partnership interest from pharma and med‑tech firms.
Risk Factors
Clinical efficacy and safety uncertainties, regulatory challenges for a drug‑device combo, and competition from existing anti‑arrhythmic agents and digital health platforms.
Competitive Landscape
Competes with amiodarone, dronedarone, and other rhythm‑control drugs, as well as wearable AF detection solutions; differentiation lies in budiodarone’s short half‑life and integrated monitoring approach.